We found for
Supporting the Era of Green Pharmaceuticals in the UK

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Payment Models for Multi-Indication Therapies

The Lower Drug Costs Now Act and Pharmaceutical Innovation

Opportunities to Increase Efficiency in Healthcare

Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

Unrelieved Pain in Palliative Care in England
